Page last updated: 2024-08-26

rubidium and Long QT Syndrome

rubidium has been researched along with Long QT Syndrome in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Culberson, JC; Kane, SA; Karczewski, J; Kiss, L; Koblan, KS; Spencer, RH; Wang, J	1
Bischoff, U; Ebneth, A; Netzer, R	1
Dunlop, J; Jow, F; Kowal, D; Maddox, T; Mekonnen, B; Shen, R; Tseng, E; Wang, K	1

Reviews

1 review(s) available for rubidium and Long QT Syndrome

Article	Year
HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery. Current opinion in drug discovery & development, 2003, Volume: 6, Issue:4 Topics: Animals; Drug Design; Drug Evaluation, Preclinical; Fluorescent Dyes; Heart; Humans; Ion Channels; Long QT Syndrome; Myocardium; Rubidium	2003

Other Studies

2 other study(ies) available for rubidium and Long QT Syndrome

Article	Year
Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel. Biochemical pharmacology, 2009, May-15, Volume: 77, Issue:10 Topics: Animals; Benzopyrans; Cell Culture Techniques; Chlorides; CHO Cells; Cricetinae; Cricetulus; Ether-A-Go-Go Potassium Channels; Humans; Ion Channel Gating; Long QT Syndrome; Models, Molecular; Mutation; Patch-Clamp Techniques; Piperidines; Potassium Channel Blockers; Protein Binding; Protein Structure, Tertiary; Rubidium; Structure-Activity Relationship; Transfection	2009
Rb+ efflux through functional activation of cardiac KCNQ1/minK channels by the benzodiazepine R-L3 (L-364,373). Assay and drug development technologies, 2006, Volume: 4, Issue:4 Topics: Animals; Anthracenes; Benzodiazepines; CHO Cells; Chromans; Cricetinae; Cyclic Nucleotide-Gated Cation Channels; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Gene Expression; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; Ion Channels; KCNQ1 Potassium Channel; Long QT Syndrome; Membrane Potentials; Myocardium; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Potassium Chloride; Rats; Reproducibility of Results; Risk Factors; Rubidium; Spectrophotometry, Atomic; Tetraethylammonium	2006

Article

Year

Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.

Biochemical pharmacology, 2009, May-15, Volume: 77, Issue:10

Topics: Animals; Benzopyrans; Cell Culture Techniques; Chlorides; CHO Cells; Cricetinae; Cricetulus; Ether-A-Go-Go Potassium Channels; Humans; Ion Channel Gating; Long QT Syndrome; Models, Molecular; Mutation; Patch-Clamp Techniques; Piperidines; Potassium Channel Blockers; Protein Binding; Protein Structure, Tertiary; Rubidium; Structure-Activity Relationship; Transfection

2009

Rb+ efflux through functional activation of cardiac KCNQ1/minK channels by the benzodiazepine R-L3 (L-364,373).

Assay and drug development technologies, 2006, Volume: 4, Issue:4

Topics: Animals; Anthracenes; Benzodiazepines; CHO Cells; Chromans; Cricetinae; Cyclic Nucleotide-Gated Cation Channels; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Gene Expression; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; Ion Channels; KCNQ1 Potassium Channel; Long QT Syndrome; Membrane Potentials; Myocardium; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Potassium Chloride; Rats; Reproducibility of Results; Risk Factors; Rubidium; Spectrophotometry, Atomic; Tetraethylammonium

2006